KLKatia Lemdani

Katia Lemdani

*This is an algorithmically generated author record based on publicly available information.

Katia Lemdani has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology

    by Augustin Suffisseau, Johanne Seguin, Katia Lemdani, Sarah Diakhaby, Claude Capron, Mostafa El Hajjam, Fabrice Ruiz, Frederique Peschaud, Nathalie Mignet, Robert Malafosse

    Purpose of Review: Locoregional therapies have emerged as key components in the therapeutic arsenal against gastrointestinal cancers, offering minimally invasive options with curative potential. Beyond their direct cytotoxic effects, these interventions can remodel the tumour microenvironment by inducing immunogenic cell death and initiating local and systemic immune responses, including abscopal effects. This review aims to examine how these immunomodulatory properties may support locoregional therapies as an ideal platform for intratumoural immunotherapy, positioning their combination at the core of the evolving field of interventional immuno-oncology. Recent Findings: Recent studies demonstrate that locoregional therapies can induce immune responses through modulation of the tumour microenvironment, creating conditions that may be exploited by intratumoural immunotherapy. This review provides a comprehensive overview of current locoregional modalities, including thermal and non-thermal ablative techniques, transarterial therapies, and minimally invasive radiation methods, detailing their mechanisms of action, clinical applications, and immune-related effects. Special attention is given to emerging evidence supporting the combination of these approaches with intratumoural delivery of immunomodulatory agents, to enhance anticancer immune responses. Summary: The convergence of locoregional intervention and targeted immunomodulation represents an emerging therapeutic concept in the treatment of gastrointestinal cancers, offering the prospect of personalised, tumour-directed immune activation. This approach holds the potential to extend the benefits of immunotherapy beyond genetically defined subgroups to a broader patient population.

  • A vaccine targeting human IgE induces long-term protection against anaphylaxis in humanized mice

    by Eva Conde, Emma Lamanna, Aurélie Mougel, Jasper B. J. Kamphuis, Alexia Loste, Julien Stackowicz, Ophélie Godon, Emilie Mauré, Cyprien Pecalvel, William P. M. Worrall, et al.

    Immunoglobulin E (IgE) antibodies play a key role in allergy and its most dangerous and life-threatening manifestation, anaphylaxis. Anti-IgE monoclonal antibodies (mAbs) have been developed to treat IgE-dependent diseases such as allergic asthma, food allergy, and chronic spontaneous urticaria. However, their use is still restricted to a minority of patients suffering from the most severe symptoms because treatment is costly and requires repeated administration. Therefore, we developed a conjugate vaccine against human IgE as a potential alternative therapy for long-term protection from IgE-dependent diseases. The IgE conjugate vaccine was generated by coupling a mutated fragment containing the Cε3-4 domains of human IgE with the carrier protein diphtheria cross-reactive material 197 (CRM 197 ) using kinoid technology to raise autoantibodies against a self-antigen by engrafting it onto the highly immunogenic CRM 197 carrier. To assess the efficacy of IgE-kinoid (IgE-K) vaccination, we generated a mouse model humanized for IgE and its high-affinity receptor FcεRI. IgE-K vaccination induced long-term production of anti–human IgE neutralizing antibodies without any detectable adverse effect. Anti-IgE antibodies were detected in the sera of IgE-K–immunized mice for up to 12 months postvaccination with a similar avidity as the approved anti-IgE mAb omalizumab. Furthermore, IgE-K vaccination protected against both IgE-mediated cutaneous and severe systemic anaphylaxis in IgE/FcεRI-humanized mice. Our results demonstrate that long-term reduction in IgE activity can be achieved through vaccination with human kinoids and can protect against anaphylaxis in humanized mice. This may represent a cost-effective, long-term therapeutic strategy for the treatment of IgE-mediated diseases.


  • Open Access

    An Anti‐IL‐13 Vaccine Reduces Atopic Dermatitis in Humanized Mice and Induces Neutralizing Antibodies in Nonhuman Primates

    by Aurélie Mougel, Katia Lemdani, Nadine Serhan, Charlotte Hateb, Jonathan Bonnefoy, Samir Hamdi, William P. M. Worrall, Jasper B. J. Kamphuis, Léna Andrieux, Fabien Colaone, et al.

  • Post-encapsulation methods for the preparation of mRNA-LNPs

    by Joanna Duffrène, Chloé Muzard, Johanne Seguin, Charlotte Izabelle, Thibaut Vrai, Tina Ejlalmanesh, Marianne Bombled, Samir Hamdi, Katia Lemdani, Khair Alhareth, et al.

    Microfluidics mixing is the current lab-scale method used for producing mRNA-loaded lipid nanoparticles (mRNA-LNPs) thanks to reproducibility and robustness of microfluidic mixing. Despite these advantages, the production of small LNP volumes is associated with significant material waste. Given the high cost of synthetic mRNA, this waste can be a major limitation, particularly for early-stage screening of formulations. This study proposes alternative methods for mRNA-LNP formulation aiming to improve their stability for both formulation and mRNA screening, while reducing material waste on a research scale. Specifically, we investigated post-encapsulation of mRNA into pre-formed vesicles (PFVs) obtained by microfluidic mixing. These PFVs were complexed with mRNA by: (1) a microfluidic or (2) a manual pipetting method. The resulting mRNA-LNPs produced using these two post-encapsulation methods exhibit similar physicochemical properties and morphologies to those obtained by conventional microfluidic protocol. These mRNA-LNPs were assessed on in vitro and in vivo expression. mRNA-LNPs prepared by our alternative methods showed a similar transfection level compared to the conventional formulation taken as a control. The suitability of post-encapsulation methods to other lipids, mRNAs and microfluidic systems was also confirmed. This work offers robust, simple and economic alternative methods for preparing small volumes of mRNA-LNPs. The versatility of post-encapsulation methods allows to screen mRNA formulations in a wide range of laboratories. These methods could be applied to encapsulate tailored doses of mRNA and various mRNA constructs to achieve an optimal and personalized therapy. Graphical abstract


  • Open Access

    Assessing IgE and basophil activity in blood samples from nonhuman primates

    by Cyprien Pecalvel, Aurélie Mougel, Edouard Leveque, Katia Lemdani, Vincent Serra, Laurent Guilleminault, Laurent L. Reber


  • Open Access

    Distinct dynamics of mRNA LNPs in mice and nonhuman primates revealed by in vivo imaging

    by Katia Lemdani, Romain Marlin, Céline Mayet, Vladimir Perkov, Quentin Pascal, Manon Ripoll, Francis Relouzat, Nina Dhooge, Laetitia Bossevot, Nathalie Dereuddre-Bosquet, et al.

    The characterization of vaccine distribution to relevant tissues after in vivo administration is critical to understanding their mechanisms of action. Vaccines based on mRNA lipid nanoparticles (LNPs) are now being widely considered against infectious diseases and cancer. Here, we used in vivo imaging approaches to compare the trafficking of two LNP formulations encapsulating mRNA following intramuscular administration: DLin-MC3-DMA (MC3) and the recently developed DOG-IM4. The mRNA formulated in DOG-IM4 LNPs persisted at the injection site, whereas mRNA formulated in MC3 LNPs rapidly migrated to the draining lymph nodes. Furthermore, MC3 LNPs induced the fastest increase in blood neutrophil counts after injection and greater inflammation, as shown by IL-1RA, IL-15, CCL-1, and IL-6 concentrations in nonhuman primate sera. These observations highlight the influence of the nature of the LNP on mRNA vaccine distribution and early immune responses.


  • Open Access

    An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates

    by Manon Ripoll, Marie-Clotilde Bernard, Céline Vaure, Emilie Bazin, Sylvie Commandeur, Vladimir Perkov, Katia Lemdani, Marie-Claire Nicolaï, Patrick Bonifassi, Antoine Kichler, et al.


  • Assessment of the targeting specificity of a fluorescent albumin conceived as a preclinical agent of the liver function

    by K. Lemdani, H. Salmon, R. Gahoual, M. Bessodes, D. Scherman, P. Houzé, J. Seguin, N. Mignet

    A liver function imaging with lactosylated labelled human albumin is introduced. Ligand and aggregates of the products are quantified before pre-clinical demonstration is achieved in a mice model of metastatic liver from colorectal cancer.


  • The anti-tumour immune response after radiofrequency ablation of colorectal cancer.

    by Katia Lemdani, Claude Capron, Johanne Seguin, Nathalie Mignet, Vincent Boudy, Frederique Peschaud, Jean Francois Emile, Robert Malafosse

    E14540 Background: Results of radiofrequency ablation (RFA), increasingly used to treat liver tumors, are compromised by local and systemic relapse. Hyperthermia related cancer cells death, release of tumor antigens and expression of danger signals activate a tumor-specific T-cells response. This effect remains ineffective to avoid recurrence. Therefore we propose to combine RFA with an activation of a solid immune antitumor response as curative treatment of a colorectal (CRC) metastatic disease in immunocompetent mouse. Methods: RFA was used to treat a CT26- luc tumor. In two distinct clinical situations, distant macroscopic or microscopic tumors were established as metastases before or at the time of RFA. Immune response was modulated by an injection in situof a thermo-reversible hydrogel loaded by GM-CSF and BCG, targeting dendritic cells. In the group of mice with large far lesions this strategy was combined with immune checkpoint inhibition. The efficiency was assessed on survival, evolution of distant lesions, characterization of lymphocyte infiltration in tumors and systemic immunity through specific TNF- α and IFN-y expression in spleen and draining lymph nodes. Results: The in situ immunogel injection after RFA resulted in a prolonged survival of mice. Regression of distant lesions was related to a strong systemic antitumor immune response and a great improvement of tumor infiltration by specific cytotoxic lymphocytes. In adjuvant situation, the use of immunogel induced a complete cure of microscopic secondary lesions without any treatment. Immune escape of large secondary lesions was reversed by association of RFA-immunogel vaccination with a systemic check point blockade, separately ineffective. Conclusions: Validation of this strategy, combining RFA of liver metastases and activation of a strong immune response controlling the residual disease, could result in a clinical assay including this approach within the standard treatment of CRC. Furthermorethe powerful synergy between RFA-in situ immunomodulation as a starter treatment and checkpoint blockade ineffective alone in CRC or after single RFA, allows reconsidering the use of immune checkpoint inhibitors in metastatic microsatellite stable CRC.